SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopust… Read more
Market Cap & Net Worth: SOL-GEL TECHN. IS-10 (4SG)
SOL-GEL TECHN. IS-10 (F:4SG) has a market capitalization of $221.61 Million (€215.90 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #25841 globally and #2819 in its home market, demonstrating a 4.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SOL-GEL TECHN. IS-10's stock price €77.50 by its total outstanding shares 2785787 (2.79 Million).
SOL-GEL TECHN. IS-10 Market Cap History: 2019 to 2026
SOL-GEL TECHN. IS-10's market capitalization history from 2019 to 2026. Data shows growth from $32.31 Million to $221.61 Million (38.01% CAGR).
SOL-GEL TECHN. IS-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SOL-GEL TECHN. IS-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4SG by Market Capitalization
Companies near SOL-GEL TECHN. IS-10 in the global market cap rankings as of March 19, 2026.
Key companies related to SOL-GEL TECHN. IS-10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
SOL-GEL TECHN. IS-10 Historical Marketcap From 2019 to 2026
Between 2019 and today, SOL-GEL TECHN. IS-10's market cap moved from $32.31 Million to $ 221.61 Million, with a yearly change of 38.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €221.61 Million | +105.03% |
| 2025 | €108.09 Million | +3680.00% |
| 2024 | €2.86 Million | -7.41% |
| 2023 | €3.09 Million | -71.88% |
| 2022 | €10.98 Million | -33.22% |
| 2021 | €16.44 Million | -26.28% |
| 2020 | €22.30 Million | -30.97% |
| 2019 | €32.31 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of SOL-GEL TECHN. IS-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $221.61 Million USD |
| MoneyControl | $221.61 Million USD |
| MarketWatch | $221.61 Million USD |
| marketcap.company | $221.61 Million USD |
| Reuters | $221.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.